Identification of Prognostic Genes for Recurrent Risk Prediction in Triple Negative Breast Cancer Patients in Taiwan

Discrepancies in the prognosis of triple negative breast cancer exist between Caucasian and Asian populations. Yet, the gene signature of triple negative breast cancer specifically for Asians has not become available. Therefore, the purpose of this study is to construct a prediction model for recurrence of triple negative breast cancer in Taiwanese patients. Whole genome expression profiling of breast cancers from 185 patients in Taiwan from 1995 to 2008 was performed, and the results were compared to the previously published literature to detect differences between Asian and Western patients. Pathway analysis and Cox proportional hazard models were applied to construct a prediction model for the recurrence of triple negative breast cancer. Hierarchical cluster analysis showed that triple negative breast cancers from different races were in separate sub-clusters but grouped in a bigger cluster. Two pathways, cAMP-mediated signaling and ephrin receptor signaling, were significantly associated with the recurrence of triple negative breast cancer. After using stepwise model selection from the combination of the initial filtered genes, we developed a prediction model based on the genes SLC22A23, PRKAG3, DPEP3, MORC2, GRB7, and FAM43A. The model had 91.7% accuracy, 81.8% sensitivity, and 94.6% specificity under leave-one-out support vector regression. In this study, we identified pathways related to triple negative breast cancer and developed a model to predict its recurrence. These results could be used for assisting with clinical prognosis and warrant further investigation into the possibility of targeted therapy of triple negative breast cancer in Taiwanese patients.

[1]  D. Carling,et al.  Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. , 2000, The Biochemical journal.

[2]  G. Prendergast.  Molecular cancer therapeutics : strategies for drug discovery and development , 2005 .

[3]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[4]  C. Takimoto.  Thymidylate Synthase Pharmacogenetics in Colorectal Cancer. , 2001, Clinical colorectal cancer.

[5]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[7]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[8]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[9]  T. Kinoshita,et al.  The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. , 2007, Breast.

[10]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[11]  Victoria Kristina Perry,et al.  Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients , 2007, International journal of cancer.

[12]  Wei Zhang,et al.  A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1 , 2010, Oncogene.

[13]  Morag Park,et al.  Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. , 2009, Cancer research.

[14]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[15]  W. Debinski,et al.  A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells , 2007, Molecular Cancer Therapeutics.

[16]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Rogel-Gaillard,et al.  A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. , 2000, Science.

[18]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Saif,et al.  Atypical Hand-and-Foot syndrome in an African American Patient treated with Capecitabine with normal DPD activity: Is there an ethnic disparity? , 2008, Cutaneous and ocular toxicology.

[20]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[21]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[22]  C. Perou,et al.  Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer , 2008, Cancer investigation.

[23]  Hideki Takahashi,et al.  Depigmenting Mechanisms of All-Trans Retinoic Acid and Retinol on B16 Melanoma Cells , 2008, Bioscience, biotechnology, and biochemistry.

[24]  S. Kuo,et al.  Triple negative breast carcinoma is a prognostic factor in Taiwanese women , 2009, BMC Cancer.

[25]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[26]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[27]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[28]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[29]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[30]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[31]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[32]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.